|
OS
|
Age (<50 vs. ≥50 years)
|
0.793
|
0.251
|
0.002
|
2.209
|
1.350–3.616
|
|
T category (T3 vs. T4)
|
0.134
|
0.452
|
0.766
|
1.144
|
0.472–2.775
|
|
N category (N0 vs. N1 vs. N2 vs. N3)
|
0.364
|
0.133
|
0.006
|
1.439
|
1.108–1.868
|
|
Sex (male vs. female)
|
−0.168
|
0.278
|
0.547
|
0.845
|
0.490–1.459
|
|
Pathologic type (WHO I vs. II–III)
|
0.415
|
0.473
|
0.380
|
1.515
|
0.599–3.830
|
|
Chemotherapy (yes vs. no)
|
−0.409
|
0.484
|
0.398
|
0.664
|
0.257–1.716
|
|
Radiation dose (<73.92 vs. ≥73.92 Gy)
|
−0.189
|
0.437
|
0.666
|
0.828
|
0.352–1.950
|
|
GTV-P (≤46.4 vs. >46.4 mL)
|
0.901
|
0.261
|
0.001
|
2.463
|
1.478–4.104
|
|
LRFS
|
Age (<50 vs. ≥50 years)
|
1.768
|
0.578
|
0.002
|
5.857
|
1.887–18.186
|
|
T category (T3 vs. T4)
|
−0.151
|
0.801
|
0.851
|
0.86
|
0.179–4.133
|
|
N category (N0 vs. N1 vs. N2 vs. N3)
|
−0.108
|
0.249
|
0.663
|
0.897
|
0.551–1.462
|
|
Sex (male vs. female)
|
0.150
|
0.571
|
0.793
|
1.162
|
0.379–3.557
|
|
Pathologic type (WHO I vs. II-III)
|
0.355
|
0.765
|
0.643
|
1.426
|
0.318–6.391
|
|
Chemotherapy (yes vs. no)
|
−0.369
|
0.776
|
0.634
|
0.691
|
0.151–3.165
|
|
Radiation dose (<73.92 vs. ≥73.92 Gy)
|
−0.659
|
1.038
|
0.525
|
0.517
|
0.068–3.956
|
|
GTV-P (≤46.4 vs. >46.4 mL)
|
1.029
|
0.520
|
0.048
|
2.798
|
1.010–7.746
|
|
DMFS
|
Age (< 50 vs. ≥ 50 years)
|
0.252
|
0.281
|
0.370
|
1.287
|
0.741–2.234
|
|
T category (T3 vs. T4)
|
0.559
|
0.543
|
0.303
|
1.749
|
0.604–5.068
|
|
N category (N0 vs. N1 vs. N2 vs. N3)
|
0.418
|
0.147
|
0.005
|
1.519
|
1.138–2.027
|
|
Sex (male vs. female)
|
−0.132
|
0.303
|
0.664
|
0.877
|
0.485–1.586
|
|
Pathologic type (WHO I vs. II-III)
|
0.255
|
0.525
|
0.627
|
1.291
|
0.461–3.611
|
|
Chemotherapy (yes vs. no)
|
−0.178
|
0.613
|
0.771
|
0.837
|
0.252–2.780
|
|
Radiation dose (<73.92 vs. ≥73.92 Gy)
|
−0.024
|
0.440
|
0.956
|
0.976
|
0.412–2.313
|
|
GTV-P (≤46.4 vs. >46.4 mL)
|
0.963
|
0.280
|
0.001
|
2.620
|
1.514–4.534
|
|
DFS
|
Age (<50 vs. ≥50 years)
|
0.535
|
0.225
|
0.018
|
1.708
|
1.098–2.656
|
|
T category (T3 vs. T4)
|
0.376
|
0.415
|
0.365
|
1.457
|
0.646–3.286
|
|
N category (N0 vs. N1 vs. N2 vs. N3)
|
0.287
|
0.118
|
0.015
|
1.333
|
1.057–1.680
|
|
Sex (male vs. female)
|
−0.114
|
0.251
|
0.649
|
0.892
|
0.545–1.459
|
|
Pathological type (WHO I vs. II-III)
|
0.423
|
0.401
|
0.292
|
1.526
|
0.695–3.350
|
|
Chemotherapy (yes vs. no)
|
−0.337
|
0.441
|
0.445
|
0.714
|
0.301–1.694
|
|
Radiation dose (< 73.92 vs. ≥ 73.92 Gy)
|
−0.105
|
0.379
|
0.781
|
0.900
|
0.428–1.891
|
|
GTV-P (≤ 46.4 vs. > 46.4 mL)
|
0.848
|
0.230
|
<0.001
|
2.335
|
1.487–3.667
|
